Major Histocompatibility Complex 2019; 26 (1): 抄録集 TEL TEL

Size: px

Start display at page:

Download "Major Histocompatibility Complex 2019; 26 (1): 抄録集 TEL TEL"

觊郎
4 years ago
Views:

1 Major Histocompatibility Complex 2019; 26 (1): 抄録集 TEL TEL

2 17 MHC 2019; 26 (1) 参加費 1 2, , ,000 会議等会場地図 TEL JR 350 m 39

3 MHC 2019; 26 (1) 17 プログラム HLA 開会の挨拶オープニングセミナー 44 HLA 一般演題 (1) 1 HLA 1) 2) 1) 1) 1) 1) 1) 2) 2 LABScreen Single Antigen Beads HLA FCM 1) 1) 1) 1) 1)2) 1) 1) 2) 3 HLA Molecular Mismatch Method HLA class II de novo DSA dndsa 4 IgG HLA 1) 1) 2) 3) 3) 1) 3) 3) 3) 1) 1) 1) 1) 2) 3) 40

4 17 MHC 2019; 26 (1) 一般演題 (2) 5 HLA 1) 1) 1) 1) 1)2) 1) 1) 2) 6 MEK 1) 1) 2) 1) 1) 1) 1) 3) 4) 1) 1) 2) 3) 4) 7 HLA-F 1) 2) Daniel E Geraghty 3) 1) 1) 2) Fred Hutchinson Cancer Research Center 3) ランチョンセミナー HLA I HLA II 後援 : 株式会社ベリタス世話人会総会特別講演 HLA Killer immunoglobulin-like receptor KIR 41

5 MHC 2019; 26 (1) シンポジウム (1) 1 HLA 2 HLA HLA 1) 2) 3) 3) 4) 1) 2) HLA 3) 4) 3 HLA 休憩シンポジウム (2) HLA 1 de novo DSA 1) 2) 1) 1) 1) 1) 2) 2 3 de novo DSA 1) 2) 2) 2) 3) 3) 4) 4) 2) 2) 2) 5) 2) 1) 2) 3) 4) 5) 意見交換会

6 17 MHC 2019; 26 (1) オープニングセミナー 44 HLA 43

7 MHC 2019; 26 (1) HLA ASHI, American Society for Histocompatibility and Immunogenetics 1 NGS Next Generation Sequencing 2 FcRn neonatal Fc receptor FcRn IgG IgG MHC I FcRn ph IgG IgA IgM 5 6 IgG FcRn Rozanolixizumab I 3 CAR-T Chimeric antigen receptor T cell CAR-T T T CAR-T CTL 2017 B ALL 2018 DLBCL FDA 4 CRISPR-Cas9 Clustered Regularly Interspaced Short Palindromic Repeats-Cas9 CRISPR-Cas9 DNA CRISPR-Cas9 PAM Hot topics Best poster Rheumatoid Arthritis, RA HLA- DRB1 71 K E DRB1*04:01 K71E RA 5 Non-HLA AMR Non-HLA MICA alloantibody AT1R, ETAR, Vimentin Autoantibody AT1R AMR nm mrna mirna HLA BOS HLA Collagen-V Col-V 6-2 DNA cell free DNA, cfdna 44

8 17 MHC 2019; 26 (1) DNA ng/ml 160 base pair 2 cfdna AMR 7 UNOS mtilda HLA UNOS API developer.unos.org/ 45

9 MHC 2019; 26 (1) 一般演題 (1) 演題番号 1 ~ 4 46

10 17 MHC 2019; 26 (1) 1 HLA 1) 2) 1) 1) 1) 1) 1) 2) HLA Donor Specific Antibody DSA HLA HLA Cw12 Cw14 B40 DR2 Cw11 DR6Y HLA DSA 47

11 MHC 2019; 26 (1) 17 2 LABScreen Single Antigen Beads HLA FCM 1) 1) 1) 1) 1)2) 1) 1) 2) HLA DSA FCM-XM FCM-XM 382 LABScreen Single Antigen Beads DSA Mean Fluorescence Intensity Mean FI T cell B cell FCM-XM MFI 7 Class I B- cell FCM-XM DSA /FCM-XM 7 FCM-XM MFI Pt/ NC >2 Class II HLA B-cell FCM-XM DSA /FCM-XM DSA / FCM-XM 4 3 FCM-XM Pt/NC >2 Class I DSA MFI T cell FCM-XM MFI R 2 = Class II DSA MFI B cell FCM-XM MFI R 2 = Class I HLA DSA T cell FCM-XM DSA /FCM-XM 7 DSA MFI DSA /FCM-XM LABScreen Single Antigen Beads FCM-XM DSA non-hla 48

12 17 MHC 2019; 26 (1) 3 HLA Molecular Mismatch Method HLA class II de novo DSA dndsa % HLAclass II dndsa HLA-DQ HLA dndsa ABMR DSA ABMR HLA HLA HLA Molecular Mismatch Method HLA HLA class II dndsa ABMR 14 non-abmr 12 2 HLA Cambridge HLA Immunogenicity algorithm EMSHMS Duquesnoy s HLA Structural Model Linear Epitope Conformational Epitope HLA C3d Luminex SAB Immucore HLA Epitope Registry HLA dndsa DSA DSA DSA EMS 31.7vs13.7 HMS 31.1vs12.0 DSA DSA EMS HMS DRB1 DRB3/4/5 DQA1/B1 EMS: 55.5vs21.4 HMS: 57.2vs19.5 P=0.0024, P= HLA dndsa C3d ABMR 36 DSA C3d DSA 30 C3d DSA non-abmr 14 DSA C3d DSA C3d(+)DSA C3d( ) DSA EMS HMS 36.9vs vs21.5 C3d(+)DSA C3d( )DSA P=0.0278, P= HLA 1 HLA class II dndsa 2 HLA-DQ HLA class II 3 DSA 49

13 MHC 2019; 26 (1) 17 4 IgG HLA 1) 1) 2) 3) 3) 1) 3) 3) 3) 1) 1) 1) 1) 2) 3) NAIT NAIT HLA HPA HLA U N HLA A26/33 B61/58 U A2/33 B51/58 N A1/26 B37/ HLA LABScreen Single Antigen OneLambda IgG A1 A2 B37 B51 U N U A2 B51 N A1 B37 A2 B51 A1 IgG A2 B51 A1 IgG1 IgG2 A2 B51 IgG1 IgG2 A1 N A2 B51 IgG3 IgG4 A2 B51 A1 IgG1 IgG2 HLA IgG3 NAIT HLA NAIT 50

14 17 MHC 2019; 26 (1) 一般演題 (2) 演題番号 5 ~ 7 51

15 MHC 2019; 26 (1) 17 5 HLA 1) 1) 1) 1) 1)2) 1) 1) 2) HLA HLA 2 HLA-C*01:02,*08:01 SSP HLA-C*01:02,*08:22 WAKFlow SSOP HLA HLA QCWS

16 17 MHC 2019; 26 (1) 6 MEK 1) 1) 2) 1) 1) 1) 1) 3) 4) 1) 1) 2) 3) 4) 1 MEK mitogen-activated protein kinase T PPARγ MEK Streptozotocin H-2b MHC H-2d 28 MEK PCR T in vitro MEK MEK 30 vs ; p<0.01 MEK 7 T MEK Effector CD4+ T cell 44.0% vs. 58.3%; p=0.03 Naïve CD4+ T cell 42.2% vs. 30.5%; p=0.02 MEK IL-2/IFN-γ MEK 24 viability MEK naïve CD4 T Effector T MEK 53

17 MHC 2019; 26 (1) 17 7 HLA-F 1) 2) Daniel E Geraghty 3) 1) 1) 2) Fred Hutchinson Cancer Research Center 3) HLA-F HLA Ib HLA-F killer immunoglobulin like receptor (KIR)-3DL2 NK HLA-F mrna HLA-F KIR HLA-F HLA-F No.1167 HLA-F HLA-F t-test; p= HLA-F HLA-F HLA-F 54

18 17 MHC 2019; 26 (1) ランチョンセミナー HLA I HLA II 55

19 MHC 2019; 26 (1) 17 HLA 1) 2) 1) 2) HLA HLA HLA One Lambda Inc. 2 HLA HLA HLA Non-HLA LABScan Luminex LABScreen Autoantibody HLA CDC FCXM DSA Donor Specific Antibody FlowDSA- XM HLA A B C DR HLA Class II DP DQ HLA DP DQ 56

20 17 MHC 2019; 26 (1) 世話人会総会 57

21 MHC 2019; 26 (1) 特別講演 HLA Killer immunoglobulin-like receptor KIR 58

22 17 MHC 2019; 26 (1) Killer immunoglobulin-like receptor KIR Natural killer NK killer immunoglobulin-like receptor KIR HLA KIR HLA NK KIR KIR Ruggeri, Science 2002 HIV AIDS KIR PCR KIR KIR KIR3DL1 HLA-B GD2 Forlenza, J Clin Oncol 2016 Boudreau, J Clin Oncol 2017 KIR KIR3DL1 Ureshino, Shindo, Cancer Immunol Res 2018 KIR KIR KIR 59

23 MHC 2019; 26 (1) シンポジウム (1) 1 HLA 2 HLA HLA 1) 2) 3) 3) 4) 1) 2) HLA 3) 4) 3 HLA 60

24 17 MHC 2019; 26 (1) 1 HLA HLA HLA HLA HLA GVHD T GVHD anti-thymogloblin ATG cyclophosphamide CY HLA GVHD super high risk GVL graft versus leukemia ATG T GVHD / GVL GVHD HLA HLA HLA full allogeneicspousal preliminary data HLA / % ATG 2.5 mg/kg tacrolimus (TAC)+ methylprednisolone (mpsl) 2 mg/kg+short-term MTX (smtx)+mycophenolate mofetil (MMF) 15 mg/kg TAC+mPSL 1 mg/kg HLA 5 62% 31% 61

25 MHC 2019; 26 (1) 17 2 HLA HLA 1) 2) 3) 3) 4) 1) 2) HLA 3) 4) graft-versus-host disease, GVHD graft-versus-leukemia effect GVL GVHD Human leukocyte antigen, HLA HLA-A, -B, -C, -DRB1 HLA 6 HLA HLA HLA- A, -B, -C, -DRB1 HLA GVHD T HLA-A, -B, -C, -DRB HLA HLA-A, -B, -C, -DRB1 8 HLA HLA HLA HLA private haplotype 0.005% 8 90% HLA 90% HLA % % HLA % % % % % % % p= DFS % % % %p= % % % % p= % % % % p= Grade II IV GVHD % % % % p=0.23 Grade III IV GVHD % % % % p=0.54 GVHD

26 17 MHC 2019; 26 (1) 36.8% % % % p=0.60 DFS PS 2 4 HR 2.54, 95%CI , vs PS 0 1 HR 0.81, 95%CI , vs TBI HR 2.21, 95%CI , vs 0 1 DFS HR 1.79, 95%CI: HLA GVHD DFS HLA GVL HLA 63

27 MHC 2019; 26 (1) 17 3 HLA HLA HLA-A, -B, -DRB1 6 2 HLA-A, -B, -C, -DRB /kg CD34 HLA HLA HLA 1 HLA 0 HLA HLA-A, -B, -C, -DRB % 82% 79% P= P= P=0.005 CD34 HLA 2 GVH Homo to hetero HLA 64

28 17 MHC 2019; 26 (1) 休憩シンポジウム (2) HLA 1 de novo DSA 1) 2) 1) 1) 1) 1) 2) 2 3 de novo DSA 1) 2) 2) 2) 3) 3) 4) 4) 2) 2) 2) 5) 2) 1) 2) 3) 4) 5) 65

29 MHC 2019; 26 (1) 17 1 de novo DSA 1) 2) 1) 1) 1) 1) 2) HLA de novo donor specific HLA antibodies: dn DSA chronic antibody mediated rejection: chronic AMR HLA chronic AMR chronic AMR HLA subclinical HLA chronic AMR HLA 179 Flow PRA screening test LABScreen single antigen test dn DSA dn DSA dn DSA dn DSA % de novo DSA dn DSA 1 4.2% 3 8.5% % dn DSA HLA-class I +class II 7 HLA-DR DR+DQ 7 HLA-DQ chronic AMR 9 T T cell mediated rejection: TCMR +AMR 1 subclinical AMR 3 13 Chronic AMR TCMR+AMR Rituximab Subclinical AMR 4 dn DSA chronic AMR 66

30 17 MHC 2019; 26 (1) 2 CDC T-cell MFI HLA FCM HLA A, B, C, DR, DQ, DP HLA CDC FCM HLA MFI< DSA MFI CDC, FCM DSA B 2 DQ 2 CDC FCM DQ 2 FCM 1 2 AMR 2 HLA HLA A, B, DR FCM 67

31 MHC 2019; 26 (1) 17 3 de novo DSA 1) 2) 2) 2) 3) 3) 4) 4) 2) 2) 2) 5) 2) 1) 2) 3) 4) 5) HLA DSA DSA de novo DSA SAB HLA DSA 17% 38% DSA 50% F2 DSA 3% p=0.001 DSA 41.4% DSA 22.4% p=0.04 DSA DSA 34% DSA 51% DSA p=0.034 DSA p= DSA DSA p= DSA DSA DSA DSA 68

第九期內文檔-新檔

第九期內文檔-新檔不可抗的致癌基因血癌治療史特稿 / 何日生中國古老智慧的太極, 陰中有陽, 陽中有陰, 一切存有都隱藏著敗破瓦解, 一切的生都預示著最終的毀滅 ; 生物的生存機制和秘密也是如此死亡的因子早就埋藏在創生的基因裡 : 在人體內, 抑